Gufic Biosciences Limited GUFICBIO NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.gufic.com

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.

Market & Price

Market Cap

₹3,347.93 Cr

Current Price

₹333.85

High / Low (52W)

₹404.44 / ₹273.50

Beta

-0.07

Valuation

Stock P/E

67.17

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹63.02

Price to Book

5.30

P/S

3.73

EV/EBITDA

30.26

Dividend Yield

0.03%

Profitability & Returns

ROCE

14.99%

ROE

ROA

Profit Margin

5.58%

Op Margin

10.93%

EPS (Latest Qtr)

₹1.24

EPS (TTM)

₹4.97

Balance Sheet & Liquidity

Debt/Equity

0.58

Quick Ratio

Current Ratio

Debt

₹369.21 Cr

Total Assets

₹1,169.36 Cr

Current Assets

₹624.52 Cr

Working Capital

₹236.97 Cr

Ownership

Promoter Holding

77.55%

Chg in Prom Hold

FII / Inst Holding

3.69%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹3,626.02 Cr

Total Revenue (TTM)

₹897.21 Cr

EBITDA

₹119.83 Cr

Free Cash Flow

Operating Cash Flow

Shares Outstanding

₹10.03 Cr

Gross Margin

55.06%

Payout Ratio

2.01%

Growth (CAGR)

Revenue 5Y

1.50%

Profit 5Y

-10.09%

Revenue (YoY)

11.40%

Earnings (YoY)

-35.80%

PROS

No notable strengths flagged.

CONS

Trading at a high P/E of 67.2.
Earnings shrank at -10.1% CAGR over 5 years.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	GUFICBIO Gufic Biosciences Limited NSEPHARMA	333.85	67.17	₹3,347.93 Cr	0.03%	14.99%	-	1.50%	-10.09%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Revenue	-	207.79 Cr	130.77 Cr	223.72 Cr	237.05 Cr	231.41 Cr
Cost of Revenue	-	94.17 Cr	97.23 Cr	100.77 Cr	104.44 Cr	101.02 Cr
Gross Profit	-	113.63 Cr	33.53 Cr	122.95 Cr	132.62 Cr	130.39 Cr
Operating Expenses	-	84.32 Cr	11.30 Cr	97.37 Cr	102.54 Cr	105.10 Cr
Operating Income	-	29.31 Cr	22.24 Cr	25.58 Cr	30.07 Cr	25.29 Cr
EBITDA	-	35.79 Cr	26.68 Cr	34.23 Cr	39.96 Cr	33.77 Cr
Interest Expense	-	4.91 Cr	8.32 Cr	9.23 Cr	9.58 Cr	8.36 Cr
Pretax Income	-	26.26 Cr	10.53 Cr	17.27 Cr	22.60 Cr	17.72 Cr
Tax Provision	-	6.96 Cr	2.81 Cr	4.20 Cr	5.78 Cr	5.30 Cr
Net Income	-	19.31 Cr	7.72 Cr	13.07 Cr	16.82 Cr	12.42 Cr
Diluted EPS	2.17	1.93	-	1.30	1.68	1.24

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Revenue	713.02 Cr	679.75 Cr	769.66 Cr	745.55 Cr
Cost of Revenue	422.82 Cr	340.90 Cr	399.29 Cr	382.27 Cr
Gross Profit	290.21 Cr	338.85 Cr	370.36 Cr	363.29 Cr
Operating Expenses	161.11 Cr	223.52 Cr	237.78 Cr	245.95 Cr
Operating Income	129.10 Cr	115.33 Cr	132.58 Cr	117.33 Cr
EBITDA	149.77 Cr	135.64 Cr	147.45 Cr	138.24 Cr
Interest Expense	4.01 Cr	6.64 Cr	14.76 Cr	23.03 Cr
Pretax Income	126.84 Cr	106.72 Cr	115.67 Cr	94.14 Cr
Tax Provision	31.00 Cr	27.02 Cr	29.54 Cr	24.49 Cr
Net Income	95.84 Cr	79.70 Cr	86.14 Cr	69.65 Cr
Diluted EPS	9.89	8.22	8.74	6.95

Compounded Sales Growth

5 Years:	1.50%
1 Year:	11.40%

Compounded Profit Growth

5 Years:	-10.09%
1 Year:	-35.80%

Stock Price Performance

1 Year:	-14.57%
6 Months:	-5.59%
3 Months:	+17.76%
1 Month:	+15.42%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Assets	521.40 Cr	861.16 Cr	1,092.54 Cr	1,169.36 Cr
Current Assets	320.75 Cr	464.11 Cr	600.48 Cr	624.52 Cr
Cash & Equivalents	11.61 Cr	28.60 Cr	1.14 Cr	15.72 Cr
Inventory	115.57 Cr	183.46 Cr	200.48 Cr	216.87 Cr
Receivables	151.55 Cr	205.47 Cr	329.94 Cr	314.61 Cr
Total Liabilities	252.28 Cr	513.35 Cr	559.98 Cr	568.29 Cr
Current Liabilities	186.40 Cr	288.21 Cr	372.05 Cr	387.56 Cr
Long Term Debt	47.98 Cr	190.68 Cr	153.96 Cr	130.50 Cr
Total Debt	64.39 Cr	334.19 Cr	332.92 Cr	336.19 Cr
Total Equity	269.12 Cr	347.81 Cr	532.56 Cr	601.08 Cr
Shares Outstanding	9.69 Cr	9.69 Cr	10.03 Cr	10.03 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Operating Cash Flow	106.24 Cr	-26.59 Cr	-7.46 Cr	122.57 Cr
Investing Cash Flow	-94.59 Cr	-190.73 Cr	-102.39 Cr	-70.78 Cr
Financing Cash Flow	-6.24 Cr	234.31 Cr	82.38 Cr	-37.20 Cr
Capital Expenditure	-87.45 Cr	-187.60 Cr	-112.69 Cr	-75.53 Cr
Free Cash Flow	18.79 Cr	-214.19 Cr	-120.15 Cr	47.04 Cr
Net Change in Cash	5.41 Cr	16.99 Cr	-27.46 Cr	14.59 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Gross Margin %	40.7%	49.8%	48.1%	48.7%
Operating Margin %	18.1%	17.0%	17.2%	15.7%
Net Margin %	13.4%	11.7%	11.2%	9.3%
ROE %	35.6%	22.9%	16.2%	11.6%
ROCE %	38.5%	20.1%	18.4%	15.0%

Shareholding Pattern

Insiders

77.55%

Institutions

3.69%

Public Float

16.42%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GUFICBIO

No recent headlines available.

GUFICBIO · Healthcare